Liquid chromatographic–mass spectrometric determination of haloperidol and its metabolites in human plasma and urine

• Published in: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences Vol. 776; no. 1; pp. 107 - 113
• Main Authors: Arinobu, Tetsuya, Hattori, Hideki, Iwai, Masae, Ishii, Akira, Kumazawa, Takeshi, Suzuki, Osamu, Seno, Hiroshi
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 25.08.2002
• Subjects: Antipsychotic Agents - blood; Antipsychotic Agents - metabolism; Antipsychotic Agents - urine; Chromatography, High Pressure Liquid - methods; Haloperidol; Haloperidol - blood; Haloperidol - metabolism; Haloperidol - urine; Humans; Mass Spectrometry - methods; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Haloperidol
• ISSN: 1570-0232; 1873-376X
• DOI: 10.1016/S1570-0232(02)00175-7

Haloperidol and its two metabolites, reduced haloperidol and 4-(4-chlorophenyl)-4-hydroxypiperidine (CPHP) in human plasma and urine were analyzed by HPLC–MS using a new polymer column (MSpak GF-310), which enabled direct injection of crude biological samples without pretreatment. Recoveries of haloperidol and reduced haloperidol spiked into plasma were 64.4–76.1% and 46.8–50.2%, respectively; those for urine were 87.3–99.4% and 94.2–98.5%, respectively; those of CPHP for both samples were not less than 92.7%. The regression equations for haloperidol, reduced haloperidol and CPHP showed good linearity in the ranges of 10–800, 15–800 and 400–800 ng/ml, respectively, for both plasma and urine. Their detection limits were 5, 10 and 300 ng/ml, respectively, for both samples. Thus, the present method was sensitive enough for detection and determination of high therapeutic and toxic levels for haloperidol and its metabolites present in biological samples.